CGChristian Gaebler

Christian Gaebler

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Christian Gaebler has a total of 396 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Post-exposure prophylaxis with a monoclonal antibody cocktail after Bundibugyo ebolavirus exposure in adults and children

    by Christian Gaebler, Han Ngoc Le, Luise Martin, Paulina Tarnow, Alexander Gratopp, Stefanie Hort, Anke Wendt, Monika Rottstegge, Pinkus Tober Lau, Matthias Zehner, et al.


  • Open Access

    A case of Bundibugyo virus disease treated with monoclonal antibodies and remdesivir

    by Alexander Uhrig, Frieder Pfäfflin, Pinkus Tober-Lau, Victor M. Corman, Miriam S. Stegemann, Paulina Tarnow, Monika Rottstegge, Katrin Moira Heim, Felix Bremer, Thomas Cronen, et al.


  • Open Access

    Sotatercept Rescue Therapy for Acute Right Heart Failure in HIV‐Associated PAH

    by Yaosi Li, Daniel Grund, Nils Kremer, Holger Müller‐Redetzky, Marie Zajonz, Christian Gaebler, Martin Witzenrath, Horst Olschewski, Athiththan Yogeswaran

    Despite major advances in antiretroviral treatment, pulmonary arterial hypertension (PAH) remains a common, severe complication in patients diagnosed with HIV. Treatment of HIV‐associated PAH targets the nitric oxide, endothelin, and prostacyclin pathways, with limited evidence for novel therapies, as these patients have been excluded from most pivotal randomized controlled trials. We report a 58‐year‐old male with HIV‐PAH on dual oral PAH‐targeted therapy who developed acute right ventricular (RV) failure triggered by sepsis. Despite escalation of guideline‐directed therapy with intravenous prostacyclin and catecholamines, the patient continued to exhibit decompensated right heart failure. Sotatercept was initiated, after which the patient showed marked improvement within 24 h, including improved echocardiographic RV function, a decline in NT‐proBNP, recovery of renal function, and successful weaning from catecholamines and prostacyclin. The patient was subsequently transferred to a general ward in stable condition. This case suggests a potential role for sotatercept as rescue therapy in acute decompensated HIV‐PAH, with a rapid temporal association with hemodynamic improvement. Further randomized controlled studies are warranted in this high‐risk population.


  • Top Cited Papers
    Open Access

    Autologous neutralizing antibodies and polyfunctional T cells contribute to long-term HIV-1 post-intervention control

    by Katie Fisher, Mauro A. Garcia, Giacomo S. Frattari, Chloé Naasz, Junlin Zhuo, Miriam Rosás-Umbert, Lisa L. Dietz, Anna Karina Juhl, Emma Falling Iversen, Rikke Olesen, et al.

    Antiretroviral therapy (ART) interruption typically leads to rapid HIV-1 viral rebound in people with HIV-1. To develop an HIV-1 cure, insight into immunological mechanisms capable of preventing HIV-1 viral rebound is urgently needed. Here, we describe three exceptional post-intervention controllers (PICs) who maintained ART-free virological control for >6.5 years (ongoing), >7.5 years (ongoing) and 2.5 years following administration of broadly neutralizing antibodies. PICs had quantifiable genetically intact/inducible infectious proviral reservoirs that were increasingly clonal and located in nongenic/centromeric chromosomal regions, indicating immune-mediated selection. Potent autologous neutralizing antibodies and polyfunctional HIV-1-specific CD4 + and CD8 + T cell responses, pre-programmed for antigen response, were present before, and persisted during, ART interruption. In one PIC, viral rebound following 2.5 years of ART-free control was associated with accumulated viral mutations that resulted in escape from neutralizing antibody and T cell responses. Collectively, our findings support developing HIV-1 curative strategies aimed at enhancing pre-existing adaptive immune responses.


  • Open Access

    Q4ddPCR: a flexible, 4-target assay for high-resolution HIV reservoir profiling

    by Rachel Scheck, Mark Melzer, Gregory Gladkov, Louise Leyre, Adam R. Ward, Daniel B. Reeves, Naomi Perkins, T. Thinh Huynh, Deborah K. McMahon, Ronald J. Bosch, et al.

    Precise and scalable quantification of the intact HIV reservoir is critical for advancing curative strategies. Current reservoir assays, such as the intact proviral DNA assay (IPDA), are limited by quantification failures or misclassification of defective proviruses due to HIV sequence heterogeneity. Q4ddPCR is a modular, droplet digital PCR simultaneously targeting four conserved regions in the HIV genome to improve specificity, reduce quantification gaps, and provide multi-layered readouts. It comprises two configurations: one fully based on Q4PCR primer/probes and one combining IPDA with gag and pol primer/probes from Q4PCR. We benchmark Q4ddPCR against 3650 near full-length proviral sequences from 13 virally suppressed people with HIV (PWH) generated by Q4PCR. Q4ddPCR closely matches sequence-confirmed reservoir measurements, and multi-probe readouts reveal clonal reservoir dynamics not detectable by IPDA. Q4ddPCR enables intact reservoir quantification in 95% of samples across four independent cohorts and in 16 PWH, strongly correlates with viral outgrowth. In longitudinal samples from 42 participants over the first 4.5 years on antiretroviral therapy (ART), Q4ddPCR reports lower proviral frequencies and a steeper decline in intact proviral DNA compared to IPDA. Collectively, our findings confirm key predictions from mathematical modeling, demonstrating that multi-target assays improve specificity and more accurately capture intact reservoir dynamics.


  • Open Access

    Sustained HIV-1 remission after heterozygous CCR5Δ32 stem cell transplantation

    by Christian Gaebler, Samad Kor, Kristina Allers, Michela Perotti, David Mwangi, Karolin Meixenberger, Kirsten Hanke, Timo Trenkner, Tom Kraus, Yequin Sha, et al.

    HIV cure is exceptionally rare, with only six cases documented among the estimated 88 million individuals who have acquired HIV since the onset of the epidemic 1–6 . Successful cures, including that of the pioneering individual known as the Berlin patient, are limited to those who received allogeneic stem cell transplants (allo-SCTs) for haematological cancers. HIV resistance from stem cell donors with the rare homozygous CCR5Δ32 mutation was long considered the main mechanism for HIV remission without antiretroviral therapy. However, recent reports have highlighted CCR5-independent mechanisms as important contributors to HIV cure 6–8 . Here we provide new evidence for this conceptual shift, whereby long, treatment-free HIV remission was achieved after allo-SCT with functionally active CCR5. A man with heterozygous CCR5 wild-type/Δ32 living with HIV received allo-SCT from a HLA-matched unrelated heterozygous CCR5 wild-type/Δ32 donor as treatment for acute myeloid leukaemia. Three years after allo-SCT, the patient discontinued antiretroviral therapy. So far, HIV remission has been sustained for more than 6 years with undetectable plasma HIV RNA. Reservoir analysis revealed intact proviral HIV before transplantation, but no replication-competent virus in blood or intestinal tissues after allo-SCT. Declining or absent HIV-specific antibody and T cell responses support the absence of viral activity. High antibody-dependent cellular cytotoxicity activity at the time of transplantation may have contributed to HIV reservoir clearance. These results demonstrate that CCR5Δ32-mediated HIV resistance is not essential for durable remission, which underscores the importance of effective viral reservoir reductions in HIV cure strategies.


  • Open Access

    Epistasis lowers the genetic barrier to SARS-CoV-2 neutralizing antibody escape

    by Leander Witte, Viren A. Baharani, Fabian Schmidt, Zijun Wang, Alice Cho, Raphael Raspe, Camila Guzman-Cardozo, Frauke Muecksch, Marie Canis, Debby J. Park, et al.

    Waves of SARS-CoV-2 infection have resulted from the emergence of viral variants with neutralizing antibody resistance mutations. Simultaneously, repeated antigen exposure has generated affinity matured B cells, producing broadly neutralizing receptor binding domain (RBD)-specific antibodies with activity against emergent variants. To determine how SARS-CoV-2 might escape these antibodies, we subjected chimeric viruses encoding spike proteins from ancestral, BA.1 or BA.2 variants to selection by 40 broadly neutralizing antibodies. We identify numerous examples of epistasis, whereby in vitro selected and naturally occurring substitutions in RBD epitopes that do not confer antibody resistance in the Wuhan-Hu-1 spike, do so in BA.1 or BA.2 spikes. As few as 2 or 3 of these substitutions in the BA.5 spike, confer resistance to nearly all of the 40 broadly neutralizing antibodies, and substantial resistance to plasma from most individuals. Thus, epistasis facilitates the acquisition of resistance to antibodies that remained effective against early omicron variants.


  • Open Access

    Antibody feedback regulates immune memory after SARS-CoV-2 mRNA vaccination

    by Dennis Schaefer-Babajew, Zijun Wang, Frauke Muecksch, Alice Cho, Maximilian Loewe, Melissa Cipolla, Raphael Raspe, Brianna Johnson, Marie Canis, Justin DaSilva, et al.

    Feedback inhibition of humoral immunity by antibodies was first documented in 19091. Subsequent studies showed that, depending on the context, antibodies can enhance or inhibit immune responses2,3. However, little is known about how pre-existing antibodies influence the development of memory B cells. Here we examined the memory B cell response in individuals who received two high-affinity anti-SARS-CoV-2 monoclonal antibodies and subsequently two doses of an mRNA vaccine4–8. We found that the recipients of the monoclonal antibodies produced antigen-binding and neutralizing titres that were only fractionally lower compared than in control individuals. However, the memory B cells of the individuals who received the monoclonal antibodies differed from those of control individuals in that they predominantly expressed low-affinity IgM antibodies that carried small numbers of somatic mutations and showed altered receptor binding domain (RBD) target specificity, consistent with epitope masking. Moreover, only 1 out of 77 anti-RBD memory antibodies tested neutralized the virus. The mechanism underlying these findings was examined in experiments in mice that showed that germinal centres formed in the presence of the same antibodies were dominated by low-affinity B cells. Our results indicate that pre-existing high-affinity antibodies bias germinal centre and memory B cell selection through two distinct mechanisms: (1) by lowering the activation threshold for B cells, thereby permitting abundant lower-affinity clones to participate in the immune response; and (2) through direct masking of their cognate epitopes. This may in part explain the shifting target profile of memory antibodies elicited by booster vaccinations9.


  • Open Access

    Memory B cell responses to Omicron subvariants after SARS-CoV-2 mRNA breakthrough infection in humans

    by Zijun Wang, Pengcheng Zhou, Frauke Muecksch, Alice Cho, Tarek Ben Tanfous, Marie Canis, Leander Witte, Brianna Johnson, Raphael Raspe, Fabian Schmidt, et al.

    Individuals who receive a third mRNA vaccine dose show enhanced protection against severe COVID-19, but little is known about the impact of breakthrough infections on memory responses. Here, we examine the memory antibodies that develop after a third or fourth antigenic exposure by Delta or Omicron BA.1 infection, respectively. A third exposure to antigen by Delta breakthrough increases the number of memory B cells that produce antibodies with comparable potency and breadth to a third mRNA vaccine dose. A fourth antigenic exposure with Omicron BA.1 infection increased variant-specific plasma antibody and memory B cell responses. However, the fourth exposure did not increase the overall frequency of memory B cells or their general potency or breadth compared to a third mRNA vaccine dose. In conclusion, a third antigenic exposure by Delta infection elicits strain-specific memory responses and increases in the overall potency and breadth of the memory B cells. In contrast, the effects of a fourth antigenic exposure with Omicron BA.1 are limited to increased strain-specific memory with little effect on the potency or breadth of memory B cell antibodies. The results suggest that the effect of strain-specific boosting on memory B cell compartment may be limited.


  • Open Access

    Humoral immunity to SARS-CoV-2 elicited by combination COVID-19 vaccination regimens

    by Zijun Wang, Frauke Muecksch, Friederike Muenn, Alice Cho, Shuai Zong, Raphael Raspe, Victor Ramos, Brianna Johnson, Tarek Ben Tanfous, Justin DaSilva, et al.

    The SARS-CoV-2 pandemic prompted a global vaccination effort and the development of numerous COVID-19 vaccines at an unprecedented scale and pace. As a result, current COVID-19 vaccination regimens comprise diverse vaccine modalities, immunogen combinations, and dosing intervals. Here, we compare vaccine-specific antibody and memory B cell responses following two-dose mRNA, single-dose Ad26.COV.2S, and two-dose ChAdOx1, or combination ChAdOx1/mRNA vaccination. Plasma-neutralizing activity, as well as the magnitude, clonal composition, and antibody maturation of the RBD-specific memory B cell compartments, showed substantial differences between the vaccination regimens. While individual monoclonal antibodies derived from memory B cells exhibited similar binding affinities and neutralizing potency against Wuhan-Hu-1 SARS-CoV-2, there were significant differences in epitope specificity and neutralizing breadth against viral variants of concern. Although the ChAdOx1 vaccine was inferior to mRNA and Ad26.COV.2S in several respects, biochemical and structural analyses revealed enrichment in a subgroup of memory B cell neutralizing antibodies with distinct RBD-binding properties resulting in remarkable potency and breadth.